ScinoPharm Taiwan Ltd
TWSE:1789

Watchlist Manager
ScinoPharm Taiwan Ltd Logo
ScinoPharm Taiwan Ltd
TWSE:1789
Watchlist
Price: 23.5 TWD -0.63% Market Closed
Market Cap: 18.6B TWD
Have any thoughts about
ScinoPharm Taiwan Ltd?
Write Note

ScinoPharm Taiwan Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ScinoPharm Taiwan Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
ScinoPharm Taiwan Ltd
TWSE:1789
Net Income (Common)
NT$403m
CAGR 3-Years
15%
CAGR 5-Years
5%
CAGR 10-Years
-7%
Y
YungShin Global Holding Corp
TWSE:3705
Net Income (Common)
NT$1.1B
CAGR 3-Years
13%
CAGR 5-Years
8%
CAGR 10-Years
4%
Formosa Laboratories Inc
TWSE:4746
Net Income (Common)
NT$255.9m
CAGR 3-Years
-48%
CAGR 5-Years
N/A
CAGR 10-Years
2%
S
SCI Pharmtech Inc
TWSE:4119
Net Income (Common)
NT$138.5m
CAGR 3-Years
N/A
CAGR 5-Years
-24%
CAGR 10-Years
-4%
Lotus Pharmaceutical Co Ltd
TWSE:1795
Net Income (Common)
NT$4B
CAGR 3-Years
42%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Standard Chem & Pharm Co Ltd
TWSE:1720
Net Income (Common)
NT$854.1m
CAGR 3-Years
10%
CAGR 5-Years
17%
CAGR 10-Years
11%
No Stocks Found

ScinoPharm Taiwan Ltd
Glance View

Market Cap
18.6B TWD
Industry
Pharmaceuticals

ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.

Intrinsic Value
16.52 TWD
Overvaluation 30%
Intrinsic Value
Price

See Also

What is ScinoPharm Taiwan Ltd's Net Income (Common)?
Net Income (Common)
403m TWD

Based on the financial report for Jun 30, 2024, ScinoPharm Taiwan Ltd's Net Income (Common) amounts to 403m TWD.

What is ScinoPharm Taiwan Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-7%

Over the last year, the Net Income (Common) growth was 54%. The average annual Net Income (Common) growth rates for ScinoPharm Taiwan Ltd have been 15% over the past three years , 5% over the past five years , and -7% over the past ten years .

Back to Top